&lt;title&gt;Photodynamic therapy with 5-aminoolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma&lt;/title&gt;

Warloe, Trond; Peng, Qian; Heyerdahl, Helèn; Moan, Johan Emelian; Steen, Harald B.; Giercksky, Karl Erik

doi:10.1117/12.203454

Cited by 55 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recurrences were observed with lesions located on the nose of the morpheiform type treated with 1.0 mg/kg BW Photofrin and a light fluence of 200-215 J/cm 2 [53]. Topical ALA at a concentration of 20% was also found to be effective in similar clinical studies [54][55][56][57][58][59].…”

Section: Basal Cell Carcinomamentioning

confidence: 56%

Perspectives of Photodynamic Therapy for Skin Diseases

Colussi¹,

Feyes²,

Mukhtar³

1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is largely an experimental modality for the treatment of neoplastic and selected nonneoplastic diseases. This therapeutic procedure, through a cascade of events, leads to cell killing. In the past few years, dermatology has taken advantage of PDT for the treatment of skin cancer and other skin diseases. The skin has considerable attributes over many other organs for the application of PDT. These include the accessibility to all three PDT essential requirements; the drug (photosensitizing agent), visible light and oxygen. The major benefit of experimental PDT in dermatology is the ability to assess the clinical response visually and the relative ease in obtaining biopsies for precise biochemical and histological analysis. Currently, PDT has received approval worldwide for the ablation of various tumor types. In the United States, the Food and Drug Administration has approved PDT for the treatment of advanced esophageal cancer and selected patients with lung cancer. Clinical trials, employing several types of photosensitizers for PDT, are ongoing for a variety of dermatological lesions. This review summarizes current knowledge of PDT in dermatology and highlights future perspectives of this modality for effective management of skin diseases.

show abstract

Section: Basal Cell Carcinomamentioning

confidence: 56%

Perspectives of Photodynamic Therapy for Skin Diseases

Colussi¹,

Feyes²,

Mukhtar³

1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…3 The concept that PDT can selectively destroy tissue has found applicability in the treatment of malignant and benign tumors involving the skin, gastrointestinal (GI) tract, retroperitoneum, genital and urinary systems, chest, central nervous system, and eye. 4 -13 PDT shows considerable promise as a primary treatment modality for localized superficial tumors 4,5,14 and is a potentially important form of adjuvant treatment for cancers of the GI tract. 8,9 The advantages of PDT include the low incidence of complications, 15 tumor responsiveness uncompromised by previous radiation or chemotherapy, subsequent use of radiation and/or chemotherapy, and repetition in multiple successive sessions.…”

Section: Discussionmentioning

confidence: 99%

Current Concepts in Gastrointestinal Photodynamic Therapy

Webber¹,

Herman²,

Kessel³

et al. 1999

Annals of Surgery

View full text Add to dashboard Cite

ObjectiveTo review current concepts of photodynamic therapy (PDT) applied to the treatment of tumors of the gastrointestinal tract. Summary Background DataPDT initially involves the uptake or production of a photosensitive compound by tumor cells. Subsequent activation of the photoreactive compound by a specific wavelength of light results in cell death, either directly or as a result of vascular compromise and/or apoptosis. MethodsThe authors selectively review current concepts relating to photosensitization, photoactivation, time of PDT application, tissue selectivity, sites of photodynamic action, PDT effects on normal tissue, limitations of PDT, toxicity of photosensitizers, application of principles of PDT to tumor detection, and current applications of PDT to tumors of the gastrointestinal tract. ResultsPDT is clearly effective for small cancers, but it is not yet clear in which cases such treatment is more effective than other currently acceptable approaches. The major side effect of PDT is cutaneous photosensitization. The major limitation of PDT is depth of tumor kill. As data from current and future clinical trials become available, a clearer perspective of where PDT fits in the treatment of cancers will be gained. Many issues regarding pharmacokinetic data of photosensitizers, newer technology involved in light sources, optimal treatment regimens that take advantage of the pharmacophysiology of photoablation, and light dosimetry still require solution. One can foresee application of differing sensitizers and light sources depending on the specific clinical situation. As technologic advances occur, interstitial PDT may have significant application.

show abstract

“…Svanberg et al [32] found that only 16 of 25 nodular BCC (64%) showed a complete remission after one single treatment, whereas 100% complete remission rate was achieved after one additional treatment. Adding a penetration enhancer, e. g. DMSO, to the ALA formulation also could improve clinical results of topical PDT for nodular lesions [33,34]. Besides ALA, there are few other sensitizers that have been used topically.…”

Section: Topical Pdt Of Skin Cancermentioning

confidence: 99%